Oltmans Curtis Gale bought FULC
February 2, 2026 · Form 4 insider transaction
Oltmans Curtis Gale bought 170,000 shares of Fulcrum Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
170,000
Price
$0.00
Total value
N/A
InsiderOltmans Curtis Gale
RoleOfficer
SecurityStock Option (right to buy)
Transaction codeA: Grant or award
Transaction dateFebruary 2, 2026
Filing dateFebruary 4, 2026
Shares owned after170,000
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.